Tag Archives: Suraj Kalia

Oppenheimer Remains a Buy on Strata Skin Sciences (SSKN)

In a report released today, Suraj Kalia from Oppenheimer maintained a Buy rating on Strata Skin Sciences (SSKN – Research Report), with a price target of $6.00. The company’s shares closed last Monday at $1.04, close to its 52-week low

Oppenheimer Remains a Hold on Intuitive Surgical (ISRG)

Oppenheimer analyst Suraj Kalia maintained a Hold rating on Intuitive Surgical (ISRG – Research Report) today. The company’s shares closed last Monday at $613.08, close to its 52-week high of $619.00. According to TipRanks.com, Kalia is a 4-star analyst with

Shockwave Medical (SWAV) Gets a Hold Rating from Oppenheimer

Oppenheimer analyst Suraj Kalia maintained a Hold rating on Shockwave Medical (SWAV – Research Report) yesterday. The company’s shares closed last Monday at $47.74. According to TipRanks.com, Kalia is a 4-star analyst with an average return of 5.8% and a

Edwards Lifesciences (EW) Receives a Buy from Oppenheimer

Oppenheimer analyst Suraj Kalia maintained a Buy rating on Edwards Lifesciences (EW – Research Report) yesterday and set a price target of $280.00. The company’s shares closed last Monday at $233.97, close to its 52-week high of $247.64. According to

Inspire Medical Systems (INSP) Receives a Sell from Oppenheimer

In a report released today, Suraj Kalia from Oppenheimer initiated coverage with a Sell rating on Inspire Medical Systems (INSP – Research Report) and a price target of $50.00. The company’s shares closed last Monday at $78.76, close to its

Nevro Crop (NVRO) Gets a Hold Rating from Oppenheimer

In a report released today, Suraj Kalia from Oppenheimer maintained a Hold rating on Nevro Crop (NVRO – Research Report). The company’s shares closed last Monday at $124.85, close to its 52-week high of $127.67. According to TipRanks.com, Kalia is